Full Press Release Details
[vc_section nav_skin=”light”][vc_row nav_skin=”light” consent_include=”include”][vc_column el_design=”{“desktop“:{“padding-top“:“6“,“padding-right“:“15“,“padding-bottom“:“6“,“padding-left“:“15“}}” css_animation=””][vc_custom_heading text=”Placental T Cells Demonstrated Greater Persistence, Resistance to Exhaustion and Efficacy Compared To Peripheral Blood Mononuclear Cells” font_container=”tag:p|text_align:center” use_theme_fonts=”yes” css=””][/vc_column][/vc_row][/vc_section][vc_row nav_skin=”light” consent_include=”include”][vc_column css_animation=””][vc_text_element css_animation=””]FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) — Celularity Inc. (NASDAQ: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that the Journal for ImmunoTherapy of Cancer, a peer-reviewed online journal of the Society for Immunotherapy of Cancer, published data highlighting the potential advantages of Celularity’s T-Cell platform for future immunotherapies including chimeric antigen receptor (CAR-T) therapies.
The data compared CAR-T cells derived from Celularity’s proprietary T cell platform with CAR-T cells derived from healthy adult peripheral blood mononuclear cells (PBMCs). CAR-T cells generated from its T-Cell platform retained stemness, maintained longer telomeres, and were more resistant to both exhaustion and immune checkpoint upregulation. Additionally, an attenuated cytokine response was observed without loss of cytotoxicity. This translated into improved and prolonged in vivo efficacy and persistence compared with healthy, adult PBMC-derived CAR-T.
“These findings help differentiate the placenta as a source of cells for immunotherapy and demonstrate the valuable potential of our placental platform for allogeneic CAR-T products,” said Dr. Robert Hariri, founder, Chairman and CEO of Celularity. “As the field of cellular immunotherapy moves towards delivering ‘one-size-fits-all’ allogeneic products, the stemness advantages inherent in our platform have the potential to translate into improved persistence and durable activity with an enhanced safety profile, offering promising prospects for developing more effective CAR-T therapies in the future. Moreover, we believe that our placental platform offers a level of scalability and consistency in manufacturing which can significantly impact the economics of delivering these therapies in the future. Through our state-of-the-art manufacturing and technical infrastructure, Celularity can be an ideal development and manufacturing partner in the cellular medicine industry.”
About Celularity Celularity Inc. (NASDAQ: CELU) is an innovative regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. What sets Celularity apart is its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Celularity’s unique approach, harnessing the placenta’s biology and ready availability, is paving the way for therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, as well as within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “intends,” “may,” “might,” “outlook,” “plan,” “possible,” “potential,” “predict,” “project,” “seek,” “should,” “strive,” “target,” “will,” “would” and the negative of terms like these or other comparable terminology, and other words or terms of similar meaning. The forward-looking statements in this press release include, without limitation, the potential advantages of Celularity’s T-Cell platform for future immunotherapies including CAR-T therapies, the potential value of Celularity’s cells as a source for allogeneic CAR-T products, the inherent stemness advantages in Celularity’s proprietary placental platform, the ability of Celularity’s CAR-T therapies to improve persistence and durable activity with an enhanced safety profile relative to PBMC derived CAR-T therapies, Celularity’s ability to offer promising prospects for developing more effective CAR-T therapies, the ability of Celularity’s placental platform to offer levels of scalability and manufacturing consistency to improve the costs, and Celularity’s ability to act as a cost effective, highly scalable development and manufacturing partner in the cellular medicine industry, among others. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including but not limited to: Celularity’s liquidity situation; the volatility in Celularity’s stock price; inherent risks in biotechnological development, including with respect to the development of novel cellular therapies; along with those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 31, 2023, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date hereof, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.[/vc_text_element][vc_empty_space][/vc_column][/vc_row][vc_row nav_skin=”light” consent_include=”include”][vc_column width=”1/2″ css_animation=””][vc_separator css_animation=””][vc_text_element css_animation=””] Investor Contact: Carlos Ramirez Celularity Inc. Carlos.ramirez@celularity.com [/vc_text_element][vc_text_element css_animation=””] Media Contact: Patrick Maddox / Michaela Fawcett KCSA Strategic Communications pmaddox@kcsa.com / mfawcett@kcsa.com [/vc_text_element][/vc_column][vc_column width=”1/2″ css_animation=””][vc_separator css_animation=””][/vc_column][/vc_row]